Search results
Results from the WOW.Com Content Network
It is used for the treatment of chronic hepatitis B virus (HBV) infection in adults with compensated liver disease [8] and is given in combination with other medications for the prevention and treatment of HIV. It is taken by mouth. [6] Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor and is a prodrug of tenofovir.
Tenofovir disoproxil is used for HIV-1 infection and chronic hepatitis B treatment. For HIV-1 infection, tenofovir is indicated in combination with other antiretroviral agents for people 2 years of age and older. For chronic hepatitis B patients, tenofovir is indicated for patients 12 years of age and older. [10]
New or worsening kidney problems, including kidney failure; Onset of depressive disorders or mood changes; Changes in bone such as osteonecrosis (breakdown and death of bone) Increases or redistribution of body fat; Immune system changes (e.g. Immune Reconstitution Syndrome)
The Centers for Disease Control and Prevention (CDC) recommends the use of emtricitabine/tenofovir for pre-exposure prophylaxis (PrEP) for uninfected, HIV-1 negative individuals that may be at risk for HIV-1 infection.
Tenofovir, also known as TDF is a so-called 'prodrug' with the active compound deactivated by a molecular side chain that dissolves in the human body allowing a low dose of tenofovir to reach the site of desired activity. One example of the prodrug form is tenofovir disoproxil fumarate with the trade name Viread (Gilead Sciences Inc USA).
Underlying hepatitis B virus (HBV) can interact with emtricitabine to cause significant liver damage, but it does not have a significant detrimental effect on the liver when given to patients without HBV. [18] Tenofovir alafenamide (TAF) is a prodrug of tenofovir that functions as a nucleotide reverse transcriptase inhibitor (NtRTI). Other ...
It is a combination of dolutegravir, lamivudine, and tenofovir disoproxil. [1] As of 2019, it is listed by the World Health Organization (WHO) as the first line treatment for adults, with tenofovir/lamivudine/efavirenz as an alternative. [2] It is taken by mouth. [3] Side effects may include trouble sleeping, weight gain, and rash.
At the time of Complera's approval, there were concerns about the US$20,500 wholesale cost of efavirenz/emtricitabine/tenofovir (Atripla), which is marketed by Gilead and Bristol-Myers Squibb. HIV drug prices have increased substantially.